医药导报2024，Vol.43Issue(9)：1434-1439,6.DOI:10.3870/j.issn.1004-0781.2024.09.013
肿瘤坏死因子α抑制药的围手术期管理
Perioperative Management of Tumor Necrosis Factor Alpha Inhibitors
摘要
Abstract
Tumor necrosis factor alpha inhibitors(TNFαi)are a class of biological agents that suppress the immune system and lower inflammatory levels,and they are increasingly employed to treat autoimmune diseases.However,TNFαi theoretically can increase the risk of infection,tumor,and other complications.To increase the safety of perioperative medicine,it is necessary to balance the relative risks of increased complication rates due to continuous medication and symptom aggravation due to medication suspension for patients undergoing surgery.Currently,there is no comprehensive clinical guideline for the perioperative management of TNFαi in China.To provide a reference for the perioperative management of TNFαi,this article used the indications of rheumatoid arthritis,ankylosing spondylitis,inflammatory bowel disease,and psoriasis as its starting point to systematically sort out the recommendations and considerations for the use of TNFαi in the perioperative drug treatment of patients.关键词
肿瘤坏死因子α抑制药/围手术期/类风湿关节炎/强直性脊柱炎/炎症性肠病/银屑病Key words
Tumor necrosis factor alpha inhibitor/Perioperative/Rheumatoid arthritis/Ankylosing spondylitis/Inflammatory bowel disease/Psoriasis分类
药学引用本文复制引用
盛梦迪,谢菡,马旭东,张海霞,李俐..肿瘤坏死因子α抑制药的围手术期管理[J].医药导报,2024,43(9):1434-1439,6.基金项目
南京大学现代医院管理与发展研究所课题项目(NDYG2021044) （NDYG2021044）
江苏省研究型医院学会精益化用药-石药专项科研基金立项项目(JY202112). （JY202112）
